Page 38 - Read Online

Mathias-Machado et al. Hepatoma Res 2021;7:67 https://dx.doi.org/10.20517/2394-5079.2021.84 Page 11 of 12

Oncotarget 2017;8:22903-16. DOI PubMed PMC
7. Okajima W, Komatsu S, Ichikawa D, et al. Liquid biopsy in patients with hepatocellular carcinoma: circulating tumor cells and cell-
free nucleic acids. World J Gastroenterol 2017;23:5650-68. DOI PubMed PMC
Hi
+
8. Ma J, Zheng B, Goswami S, et al. PD1 CD8 T cells correlate with exhausted signature and poor clinical outcome in hepatocellular
carcinoma. J Immunother Cancer 2019;7:331. DOI PubMed PMC
9. Sun HC, Tang ZY, Wang L, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in
patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol
2006;132:458-65. DOI PubMed
10. Zhang W, Song TQ, Zhang T, et al. Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from
hepatocellular carcinoma following curative treatment: a meta-analysis with comparison of different types of hepatitis. Mol Clin Oncol
2014;2:1125-34. DOI PubMed PMC
11. Yin J, Li N, Han Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B
virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol 2013;31:3647-55. DOI PubMed
12. Wang Z, Ren Z, Chen Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a
randomized controlled study. Clin Cancer Res 2018;24:2074-81. DOI PubMed
13. Wei W, Jian PE, Li SH, et al. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma
patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. Cancer Commun (Lond)
2018;38:61. DOI PubMed PMC
14. Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med 2008;359:378-90. DOI PubMed
15. Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a
phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015;16:1344-54. DOI PubMed
16. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular
carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73. DOI PubMed
17. Bruix J, da Fonseca LG, Reig M. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat Rev
Gastroenterol Hepatol 2019;16:617-30. DOI PubMed
18. Xia Y, Qiu Y, Li J, et al. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection:
a randomized controlled trial. Ann Surg Oncol 2010;17:3137-44. DOI PubMed
19. Chen K, Xia Y, Wang H, Xiao F, Xiang G, Shen F. Adjuvant iodine-125 brachytherapy for hepatocellular carcinoma after complete
hepatectomy: a randomized controlled trial. PLoS One 2013;8:e57397. DOI PubMed PMC
20. Gabrielson A, Wu Y, Wang H, et al. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC. Cancer
Immunol Res 2016;4:419-30. DOI PubMed PMC
21. Chen DS, Hurwitz H. Combinations of bevacizumab with cancer immunotherapy. Cancer J 2018;24:193-204. DOI PubMed
22. von Felden J, Craig AJ, Garcia-Lezana T, et al. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in
advanced hepatocellular carcinoma. Oncogene 2021;40:140-51. DOI PubMed
23. Brown ZJ, Greten TF, Heinrich B. Adjuvant treatment of hepatocellular carcinoma: prospect of immunotherapy. Hepatology
2019;70:1437-42. DOI PubMed
24. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular
carcinoma: a randomised trial. Lancet 2000;356:802-7. DOI PubMed
25. Lee JH, Tak WY, Lee Y, et al. Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized
phase II study. Oncoimmunology 2017;6:e1328335. DOI PubMed PMC
26. Kuang M, Peng BG, Lu MD, et al. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of
hepatocellular carcinoma. Clin Cancer Res 2004;10:1574-9. DOI PubMed
27. Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
N Engl J Med 2020;382:1894-905. DOI PubMed
28. Yau T, Kang YK, Kim TY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular
carcinoma previously treated with sorafenib: The CheckMate 040 randomized clinical trial. JAMA Oncol 2020;6:e204564. DOI
PubMed PMC
29. Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with
sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52. DOI PubMed
30. Kudo M, Ueshima K, Nakahira S, et al. Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or
radiofrequency ablation (RFA) (NIVOLVE): a phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis.
JCO 2021;39:4070. DOI
31. Liu J, Wang S, Zhang Y, Fan HT, Lin HS. Traditional Chinese medicine and cancer: History, present situation, and development.
Thorac Cancer 2015;6:561-9. DOI PubMed PMC
32. Chen Q, Shu C, Laurence AD, et al. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised
clinical trial. Gut 2018;67:2006-16. DOI PubMed
33. Zhai XF, Liu XL, Shen F, Fan J, Ling CQ. Traditional herbal medicine prevents postoperative recurrence of small hepatocellular
carcinoma: a randomized controlled study. Cancer 2018;124:2161-8. DOI PubMed
34. Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol 2013;30:3-11. DOI
PubMed PMC